Various MP clinical trials
| Trial no. . | Trial title . | Status . |
|---|---|---|
| NCT02338050 | Moxetumomab pasudotox in children with B-lineage acute lymphoblastic leukemia and minimal residual disease prior to allogeneic hematopoietic stem cell transplantation | Terminated |
| NCT02227108 | Study in pediatrics with relapsed or refractory pediatric acute lymphoblastic leukemia (pALL) or lymphoblastic lymphoma | Terminated (lack of required efficacy in first 32 patients enrolled) |
| NCT01891981 | Study of moxetumomab pasudotox in patients with relapsed and/or refractory acute lymphoblastic leukemia (ALL) | Terminated (did not proceed to the phase II terminated early by the sponsor) |
| NCT00587457 | A phase I, multicenter, dose escalation study of CAT-8015 in participants with chronic leukemia | Terminated (the study is terminated early due to unavailability of investigational product) |
| NCT01030536 | Safety study of CAT-8015 to treat advanced B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia (NHL or CLL) | Terminated (prioritization of resources) |
| Trial no. . | Trial title . | Status . |
|---|---|---|
| NCT02338050 | Moxetumomab pasudotox in children with B-lineage acute lymphoblastic leukemia and minimal residual disease prior to allogeneic hematopoietic stem cell transplantation | Terminated |
| NCT02227108 | Study in pediatrics with relapsed or refractory pediatric acute lymphoblastic leukemia (pALL) or lymphoblastic lymphoma | Terminated (lack of required efficacy in first 32 patients enrolled) |
| NCT01891981 | Study of moxetumomab pasudotox in patients with relapsed and/or refractory acute lymphoblastic leukemia (ALL) | Terminated (did not proceed to the phase II terminated early by the sponsor) |
| NCT00587457 | A phase I, multicenter, dose escalation study of CAT-8015 in participants with chronic leukemia | Terminated (the study is terminated early due to unavailability of investigational product) |
| NCT01030536 | Safety study of CAT-8015 to treat advanced B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia (NHL or CLL) | Terminated (prioritization of resources) |